Open AccessPerformance Evaluation of the BD SARS-CoV-2 Reagents for the BD MAX System
Author(s) -
Karen Yanson,
William D. LaViers,
Lori A. Neely,
Elizabeth Lockamy,
Luis Carlos Castillo-Hernandez,
Christopher Oldfied,
Ronald Ackerman,
Jamie Ackerman,
Daniel A. Ortiz,
Sixto Pacheco,
Patricia J. Simner,
Stephen Young,
Erin McElvania,
Charles K. Cooper
Publication year - 2021
Publication title -
journal of clinical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.349
H-Index - 255
eISSN - 1070-633X
pISSN - 0095-1137
DOI - 10.1128/jcm.01019-21
Subject(s) - covid-19 , nucleic acid amplification tests , virology , medicine , infectious disease (medical specialty) , outbreak , disease , chlamydia trachomatis
Nucleic acid amplification testing (NAAT) for SARS-CoV-2 is the standard approach for confirming COVID-19 cases. This study compared results between two emergency use authorization (EUA) NAATs, with two additional EUA NAATs utilized for discrepant testing.